MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises

被引:36
|
作者
Cortinovis, D. [1 ]
Monica, V. [2 ]
Pietrantonio, F. [3 ]
Ceresoli, G. L. [4 ]
La Spina, C. M. [4 ]
Wannesson, L. [5 ]
机构
[1] San Gerardo Hosp, Oncol Unit, Monza, Italy
[2] Univ Turin, San Luigi Hosp, Dept Oncol, Orbassano, Italy
[3] Ist Nazl Studio & Cura Tumori, Oncol Unit, I-20133 Milan, Italy
[4] Clin Humanitas Gavazzeni, Oncol Unit, Bergamo, Italy
[5] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
关键词
miRNA; prognostic; predictive; therapy; NSCLC; SMALL RNAS; ADJUVANT CHEMOTHERAPY; ADENOCARCINOMA CELLS; EXPRESSION SIGNATURE; REDUCED EXPRESSION; PREDICTS SURVIVAL; RESISTANCE; DIAGNOSIS; DOCETAXEL; PROGNOSIS;
D O I
10.2174/13816128113196660755
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A biological characterization of tumor tissue is mandatory in NSCLC patients to identify cases at high risk of recurrence and to drive current targeted therapies such as EGFR and ALK inhibitors. In addition, promising results have been reported on the utility of molecular parameters for the prediction of the efficacy of systemic cytotoxic therapy. MicroRNAs ( miRNAs) are small single stranded non-coding RNA molecules, which regulate gene expression at the posttranscriptional level. Growing evidence suggests that miRNAs are expressed aberrantly in many human cancers and that they play a significant role in carcinogenesis and cancer progression. There is increasing evidence that miRNA profiling may become an accurate way to differentiate tumor subtypes, determine prognosis and response to therapy. This review aims to summarize the current literature on this rapidly evolving field.
引用
收藏
页码:3982 / 3990
页数:9
相关论文
共 50 条
  • [21] CURRENT STATUS OF TARGETED THERAPY IN NON-SMALL CELL LUNG CANCER
    Parums, D. V.
    DRUGS OF TODAY, 2014, 50 (07) : 503 - 525
  • [22] Non-small cell lung cancer: current treatment and future advances
    Zappa, Cecilia
    Mousa, Shaker A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2016, 5 (03) : 288 - 300
  • [23] The current status of targeted therapy for non-small cell lung cancer
    Francis, H.
    Solomon, B.
    INTERNAL MEDICINE JOURNAL, 2010, 40 (09) : 611 - 618
  • [24] The current status of docetaxel for advanced non-small cell lung cancer
    Green, MR
    ANTI-CANCER DRUGS, 2001, 12 : S11 - S16
  • [25] MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer
    Weidle, Ulrich H.
    Birzele, Fabian
    Nopora, Adam
    CANCER GENOMICS & PROTEOMICS, 2019, 16 (02) : 99 - 119
  • [26] Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer
    Davies, A
    Gandara, DR
    Lara, P
    Goldberg, Z
    Roberts, P
    Lau, D
    SEMINARS IN ONCOLOGY, 2002, 29 (03) : 10 - 16
  • [27] BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
    Yan, Ningning
    Guo, Sanxing
    Zhang, Huixian
    Zhang, Ziheng
    Shen, Shujing
    Li, Xingya
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer
    Liu, Xingyu
    Xing, Huifang
    Liu, Hongyu
    Chen, Jun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (04) : 335 - 343
  • [29] Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions
    Riudavets, Mariona
    Cascetta, Priscilla
    Planchard, David
    LUNG CANCER, 2022, 169 : 102 - 114
  • [30] Current Status and Future Directions of Multimodality Therapy for Non-Small Cell Lung Cancer of the Superior Sulcus
    Sanborn, Rachel E.
    Thomas, Charles R.
    CURRENT CANCER THERAPY REVIEWS, 2011, 7 (01) : 2 - 9